Magellan Health (NASDAQ:MGLN) Receives News Sentiment Rating of 0.09

Media headlines about Magellan Health (NASDAQ:MGLN) have trended somewhat positive on Thursday, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Magellan Health earned a news impact score of 0.09 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.8705020982066 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the news stories that may have impacted Accern’s scoring:

Magellan Health (NASDAQ:MGLN) traded up $1.90 during mid-day trading on Thursday, reaching $98.30. The company’s stock had a trading volume of 179,119 shares, compared to its average volume of 143,844. The company has a market cap of $2,350.00, a PE ratio of 21.80, a PEG ratio of 1.23 and a beta of 0.54. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.21 and a current ratio of 2.28. Magellan Health has a 52-week low of $64.05 and a 52-week high of $98.35.

Magellan Health (NASDAQ:MGLN) last posted its quarterly earnings data on Wednesday, November 1st. The company reported $1.64 EPS for the quarter, topping the Zacks’ consensus estimate of $1.40 by $0.24. Magellan Health had a net margin of 1.68% and a return on equity of 9.20%. The company had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the business posted $1.39 EPS. The company’s quarterly revenue was up 9.9% on a year-over-year basis. equities analysts expect that Magellan Health will post 5.19 earnings per share for the current year.

Several brokerages have recently commented on MGLN. BidaskClub raised Magellan Health from a “buy” rating to a “strong-buy” rating in a report on Thursday. Raymond James Financial reaffirmed a “hold” rating on shares of Magellan Health in a report on Saturday, December 2nd. KeyCorp set a $105.00 target price on shares of Magellan Health and gave the company a “buy” rating in a research report on Friday, December 1st. Zacks Investment Research cut shares of Magellan Health from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Finally, ValuEngine upgraded shares of Magellan Health from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Magellan Health presently has a consensus rating of “Buy” and an average price target of $90.50.

In related news, CEO Mostafa Kamal sold 2,180 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $92.00, for a total value of $200,560.00. Following the completion of the sale, the chief executive officer now directly owns 2,180 shares in the company, valued at approximately $200,560. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jeffrey N. West sold 25,316 shares of the firm’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $85.85, for a total transaction of $2,173,378.60. Following the sale, the senior vice president now owns 29,243 shares of the company’s stock, valued at $2,510,511.55. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 312,637 shares of company stock valued at $27,300,118. Company insiders own 3.60% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at

Magellan Health Company Profile

Magellan Health, Inc is engaged in the healthcare management business. The Company’s segments include Healthcare, Pharmacy Management and Corporate. It is focused on managing special populations, complete pharmacy benefits and other specialty areas of healthcare. Its Healthcare includes its management of behavioral healthcare services and employee assistance program (EAP) services, management of other specialty areas, including diagnostic imaging and musculoskeletal management, and the integrated management of physical, behavioral and pharmaceutical healthcare for special populations, delivered through Magellan Complete Care (MCC).

Insider Buying and Selling by Quarter for Magellan Health (NASDAQ:MGLN)

Receive News & Ratings for Magellan Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magellan Health Inc and related companies with's FREE daily email newsletter.

Leave a Reply